Literature DB >> 29610747

Sodium-glucose cotransporter-2 inhibitors and cardiovascular outcomes: insights from the CVD-REAL study.

Marwan Saad1,2.   

Abstract

Entities:  

Year:  2018        PMID： 29610747      PMCID： PMC5879533          DOI： 10.21037/atm.2017.11.08

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  24 in total

Review 1.  SGLT2 inhibition--a novel strategy for diabetes treatment.

Authors:  Edward C Chao; Robert R Henry
Journal:  Nat Rev Drug Discov       Date:  2010-05-28       Impact factor: 84.694

2.  EMPA-REG - the "diuretic hypothesis".

Authors:  John McMurray
Journal:  J Diabetes Complications       Date:  2015-10-21       Impact factor: 2.852

3.  Association of Cardiometabolic Multimorbidity With Mortality.

Authors:  Emanuele Di Angelantonio; Stephen Kaptoge; David Wormser; Peter Willeit; Adam S Butterworth; Narinder Bansal; Linda M O'Keeffe; Pei Gao; Angela M Wood; Stephen Burgess; Daniel F Freitag; Lisa Pennells; Sanne A Peters; Carole L Hart; Lise Lund Håheim; Richard F Gillum; Børge G Nordestgaard; Bruce M Psaty; Bu B Yeap; Matthew W Knuiman; Paul J Nietert; Jussi Kauhanen; Jukka T Salonen; Lewis H Kuller; Leon A Simons; Yvonne T van der Schouw; Elizabeth Barrett-Connor; Randi Selmer; Carlos J Crespo; Beatriz Rodriguez; W M Monique Verschuren; Veikko Salomaa; Kurt Svärdsudd; Pim van der Harst; Cecilia Björkelund; Lars Wilhelmsen; Robert B Wallace; Hermann Brenner; Philippe Amouyel; Elizabeth L M Barr; Hiroyasu Iso; Altan Onat; Maurizio Trevisan; Ralph B D'Agostino; Cyrus Cooper; Maryam Kavousi; Lennart Welin; Ronan Roussel; Frank B Hu; Shinichi Sato; Karina W Davidson; Barbara V Howard; Maarten J G Leening; Maarten Leening; Annika Rosengren; Marcus Dörr; Dorly J H Deeg; Stefan Kiechl; Coen D A Stehouwer; Aulikki Nissinen; Simona Giampaoli; Chiara Donfrancesco; Daan Kromhout; Jackie F Price; Annette Peters; Tom W Meade; Edoardo Casiglia; Debbie A Lawlor; John Gallacher; Dorothea Nagel; Oscar H Franco; Gerd Assmann; Gilles R Dagenais; J Wouter Jukema; Johan Sundström; Mark Woodward; Eric J Brunner; Kay-Tee Khaw; Nicholas J Wareham; Eric A Whitsel; Inger Njølstad; Bo Hedblad; Sylvia Wassertheil-Smoller; Gunnar Engström; Wayne D Rosamond; Elizabeth Selvin; Naveed Sattar; Simon G Thompson; John Danesh
Journal:  JAMA       Date:  2015-07-07       Impact factor: 56.272

4.  Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.

Authors:  Julio Rosenstock; Ante Jelaska; Guillaume Frappin; Afshin Salsali; Gabriel Kim; Hans J Woerle; Uli C Broedl
Journal:  Diabetes Care       Date:  2014-06-14       Impact factor: 19.112

5.  Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus.

Authors:  Christopher S Kovacs; Veeraswamy Seshiah; Ludwig Merker; Anita Vedel Christiansen; Flavien Roux; Afshin Salsali; Gabriel Kim; Peter Stella; Hans-Juergen Woerle; Uli C Broedl
Journal:  Clin Ther       Date:  2015-06-29       Impact factor: 3.393

6.  SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study.

Authors:  Muhammad Abdul-Ghani; Stefano Del Prato; Robert Chilton; Ralph A DeFronzo
Journal:  Diabetes Care       Date:  2016-05       Impact factor: 19.112

Review 7.  A Review of Sodium Glucose Co-transporter 2 Inhibitors Canagliflozin, Dapagliflozin and Empagliflozin.

Authors:  Saad Hussain Syed; Sucheta Gosavi; Waseem Shami; Marco Bustamante; Zul Farah; Muhammad Teleb; Aamer Abbas; Sarmad Said; Debabrata Mukherjee
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2015

8.  Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis.

Authors:  Karen M Hallow; Gabriel Helmlinger; Peter J Greasley; John J V McMurray; David W Boulton
Journal:  Diabetes Obes Metab       Date:  2017-11-15       Impact factor: 6.577

9.  Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).

Authors:  Mikhail Kosiborod; Matthew A Cavender; Alex Z Fu; John P Wilding; Kamlesh Khunti; Reinhard W Holl; Anna Norhammar; Kåre I Birkeland; Marit Eika Jørgensen; Marcus Thuresson; Niki Arya; Johan Bodegård; Niklas Hammar; Peter Fenici
Journal:  Circulation       Date:  2017-05-18       Impact factor: 29.690

10.  The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.

Authors:  David Zi Cherney; Bruce A Perkins; Nima Soleymanlou; Ronnie Har; Nora Fagan; Odd Erik Johansen; Hans-Juergen Woerle; Maximilian von Eynatten; Uli C Broedl
Journal:  Cardiovasc Diabetol       Date:  2014-01-29       Impact factor: 9.951
View more
  2 in total

Review 1.  SGLT2 Inhibitors and Cardiovascular Outcomes: Do they Differ or there is a Class Effect? New Insights from the EMPA-REG OUTCOME trial and the CVD-REAL Study.

Authors:  Georgios Kyriakos; Lourdes V Quiles-Sanchez; Anna Garmpi; Paraskevi Farmaki; Konstantina Kyre; Spyridon Savvanis; Vasileios K Antoniou; Eleni Memi
Journal:  Curr Cardiol Rev       Date:  2020

2.  Healthcare Costs and Resource Utilization Associated with the Use of Empagliflozin Versus Other Antihyperglycemic Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease: A Real-World Retrospective Cohort Analysis.

Authors:  Aditya Raju; Pratik Pimple; Dana Stafkey-Mailey; Eileen Farrelly; Sharash Shetty
Journal:  Diabetes Ther       Date:  2021-11-02       Impact factor: 2.945
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.